Over the last twenty years or so, our relationship with our animal companions has changed dramatically. They are now members of the family.

U.S. consumers spent approximately $69.4 billion on their pets in 2017, according to the American Pet Products Association, an increase of $28.2 billion from 2007.1 Last year, 68% of U.S. households owned a pet, which translates to an estimated 89.7 million dogs and 94.2 million cats currently living in the United States.1

Today, there is a critical need for innovative medicines for animal companions, but few companies are dedicated to developing such therapies.

KindredBio is focused on bringing groundbreaking human products and innovative new technologies to veterinary medicine.

Our core strategy is to modify, improve, and repurpose pre-existing drugs and therapeutics that have already proven to be safe and effective in humans. We are developing therapies for feline, canine and equine patients, using proven human biologics.

Thanks to this strategy, we will avoid the typical 5% to 10% success rate seen with new chemical entities in traditional drug development: our goal is to achieve 50% to 70% success rate.

In addition, we develop our therapeutics for an average of approximately $5 to $8 million in only 5 to 6 years. Typical veterinary drugs reach peak sales between $10 million and $100 million per year. The market for veterinary drugs may only be one tenth the size of the human market, but the development cost of veterinary drugs is about one hundred times cheaper. In other words, our return on investment is very attractive.

We are a pioneer in animal biotechnology. We have an industry-leading scientific team and a robust pipeline.

1 American Pet Products Association. [Access Date:  January 29, 2018].  Available from: